Fulltext

Peptide receptor radionuclide therapy in a patient with disabling non-functioning pituitary adenoma

Komor, Jan ; Reubi, Jean ; Christ, Emanuel

In: Pituitary, 2014, vol. 17, no. 3, p. 227-231

Ajouter à la liste personnelle
    Titre
    • Peptide receptor radionuclide therapy in a patient with disabling non-functioning pituitary adenoma
    Auteur
    • Komor, Jan. Bühlstrasse 5, 3012, Bern, Switzerland
    • Reubi, Jean. Cell Biology and Experimental Cancer Research, Institute of Pathology, University of Bern, Bern, Switzerland
    • Christ, Emanuel. Division of Endocrinology, Diabetology and Clinical Nutrition, University Hospital of Bern, Inselspital, 3010, Bern, Switzerland
    Type de document
    • Postprint
    Langue
    • Anglais
    Publié dans
    • Pituitary, 2014, vol. 17, no. 3, p. 227-231. Springer US; http://www.springer-ny.com
    Autre version électronique
    Identifiant OAI-PMH
    • oai:doc.rero.ch:324767
    Summary
    Non-functioning pituitary adenoma (NFPA) with higher proliferation index (WHO II) are often a therapeutical challenge. Low somatostatin receptor expression in these tumors usually prevents a treatment with somatostatin analogs. In 1996, a 55-year-old patient was referred due to right-sided headache. A pituitary macroadenoma with infiltration into the right cavernous sinus was diagnosed. There was no visual field deficit and the clinical and biochemical work up was consistent with a NFPA. The patient underwent transsphenoidal surgery. Residual adenoma remained in the right cavernous sinus. Histologically, a null-cell adenoma with a high proliferation index was documented (MIB-1: 11.6%, WHO II). Somatostatin receptor autoradiography was performed in the surgical specimen showing a homogenous expression of sst2 receptors. Radiosurgery was completed with stable disease for 8years. In 2004, the patient was diagnosed with an incomplete palsy of the right oculomotorius nerve and a significant increase in the volume of the adenoma in the right cavernous sinus. After a positive Octreoscan® the patient consented to an experimental therapy approach using Lutetium DOTATOC (3×200mCi). The palsy of the oculomotorius nerve improved and remained stable until today (March 2013), the follow-up MRI scans demonstrated stable disease. This is the first case of a patient with a NFPA (WHO II) in whom PRRT successfully improved the local complications of the tumor for more than 8years after ineffective surgery and gamma knife therapy. The determination of sst2 in vitro using autoradiography and in vivo by Octreoscan was instrumental to administer this therapy in a challenging situation.